Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects

Oncotarget

Volumn 7, Issue 15, 2016, Pages 20532-20548

  Mori, Federica ^a   Ferraiuolo, Maria ^a   Santoro, Raffaela ^a   Sacconi, Andrea ^a   Goeman, Frauke ^a   Pallocca, Matteo ^a   Pulito, Claudio ^a   Korita, Etleva ^a   Fanciulli, Maurizio ^a   Muti, Paola ^b   Blandino, Giovanni ^a,b   Strano, Sabrina ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Melatonin; MiR 24; P53; PML; RNA Seq

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; HISTONE H2AX; MELATONIN; MICRORNA 24; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MICRORNA; MIRN24 MICRORNA, HUMAN; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL SHAPE; CELL TRANSFORMATION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GENE TARGETING; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OVERALL SURVIVAL; RNA METABOLISM; RNA PROCESSING; UPREGULATION; APOPTOSIS; BREAST TUMOR; CASE CONTROL STUDY; COLON TUMOR; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL PROLIFERATION; COLONIC NEOPLASMS; FEMALE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; HUMANS; MELATONIN; MICRORNAS; PROGNOSIS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84964757107     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7978     Document Type: Article

References (78)

1. Aoki H, Ozeki Y, Yamada N. Hypersensitivity of melatonin suppression in response to light in patients with delayed sleep phase syndrome. Chronobiology international. 2001; 18:263-271.
2. Arendt J, Aldhous M, Marks V. Alleviation of jet lag by melatonin: preliminary results of controlled double blind trial. British medical journal. 1986; 292:1170.
3. Carbajo-Pescador S, Garcia-Palomo A, Martin-Renedo J, Piva M, Gonzalez-Gallego J, Mauriz JL. Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: role of the MT1 receptor. Journal of pineal research. 2011; 51:463-471.
4. Cuesta S, Kireev R, Forman K, Garcia C, Escames G, Ariznavarreta C, Vara E, Tresguerres JA. Melatonin improves inflammation processes in liver of senescence-accelerated prone male mice (SAMP8). Experimental gerontology. 2010; 45:950-956.
5. Jones CR, Campbell SS, Zone SE, Cooper F, DeSano A, Murphy PJ, Jones B, Czajkowski L, Ptacek LJ. Familial advanced sleep-phase syndrome: A short-period circadian rhythm variant in humans. Nature medicine. 1999; 5:1062-1065.
6. Kim CH, Yoo YM. Melatonin Induces Apoptotic Cell Death via p53 in LNCaP Cells. The Korean journal of physiology and pharmacology. 2010; 14:365-369.
7. Lipton J, Megerian JT, Kothare SV, Cho YJ, Shanahan T, Chart H, Ferber R, Adler-Golden L, Cohen LE, Czeisler CA, Pomeroy SL. Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma. Neurology. 2009; 73:323-325.
8. Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life sciences. 1999; 65:415-420.
9. Reiter RJ, Manchester LC, Tan DX. Neurotoxins: free radical mechanisms and melatonin protection. Current neuropharmacology. 2010; 8:194-210.
10. Santoro R, Marani M, Blandino G, Muti P, Strano S. Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. Oncogene. 2012; 31:2931-2942.
11. Santoro R, Mori F, Marani M, Grasso G, Cambria MA, Blandino G, Muti P, Strano S. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. Carcinogenesis. 2013; 34:1051-1061.
12. Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, Mayo JC, Kohen R, Allegra M, Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Current topics in medicinal chemistry. 2002; 2:181-197.
13. Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, Grioni S, Sempos CT, Cavalleri A, Schunemann HJ, Strano S, Muti P. Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer epidemiology, biomarkers and prevention 2010; 19:729-737.
14. Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, Sieri S, Sempos CT, Cavalleri A, Schunemann HJ, Strano S, Muti P. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute. 2008; 100:898-905.
15. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer epidemiology, biomarkers and prevention. 2009; 18:74-79.
16. Chan AS, Lai FP, Lo RK, Voyno-Yasenetskaya TA, Stanbridge EJ, Wong YH. Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxinsensitive and-insensitive G proteins. Cellular signalling. 2002; 14:249-257.
17. Witt-Enderby PA, Li PK. Melatonin receptors and ligands. Vitamins and hormones. 2000; 58:321-354.
18. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, et al. miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumors. EMBO molecular medicine. 2012; 4:1214-1229.
19. Blandino G, Fazi F, Donzelli S, Kedmi M, Sas-Chen A, Muti P, Strano S, Yarden Y. Tumor suppressor microRNAs: a novel non-coding alliance against cancer. FEBS letters. 2014; 588:2639-2652.
20. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature reviews Cancer. 2006; 6:857-866.
21. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nature reviews Genetics. 2009; 10:704-714.
22. Kim VN, Nam JW. Genomics of microRNA. Trends in genetics. 2006; 22:165-173.
23. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
24. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004; 432:231-235.
25. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R. The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004; 432:235-240.
26. Landthaler M, Yalcin A, Tuschl T. The human DiGeorge syndrome critical region gene 8 and Its D. melanogaster homolog are required for miRNA biogenesis. Current biology. 2004; 14:2162-2167.
27. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425:415-419.
28. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. Rna. 2004; 10:185-191.
29. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science. 2004; 303:95-98.
30. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes and development. 2003; 17:3011-3016.
31. Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G, Mello CC. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell. 2001; 106:23-34.
32. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNAinterference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001; 293:834-838.
33. Slezak-Prochazka I, Durmus S, Kroesen BJ, van den Berg A. MicroRNAs, macrocontrol: regulation of miRNA processing. Rna. 2010; 16:1087-1095.
34. Bhayani MK, Calin GA, Lai SY. Functional relevance of miRNA sequences in human disease. Mutation research. 2012; 731:14-19.
35. Ma L, Teruya-Feldstein J, Weinberg RA. Tumor invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449:682-688.
36. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Yarden Y, Domany E, Blandino G. The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination. Cell cycle. 2013; 12:2371-2375.
37. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008; 454:56-61.
38. Fukuda T, Yamagata K, Fujiyama S, Matsumoto T, Koshida I, Yoshimura K, Mihara M, Naitou M, Endoh H, Nakamura T, Akimoto C, Yamamoto Y, Katagiri T, et al. DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nature cell biology. 2007; 9:604-611.
39. Sakamoto S, Aoki K, Higuchi T, Todaka H, Morisawa K, Tamaki N, Hatano E, Fukushima A, Taniguchi T, Agata Y. The NF90-NF45 complex functions as a negative regulator in the microRNA processing pathway. Molecular and cellular biology. 2009; 29:3754-3769.
40. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature. 2009; 460:529-533.
41. Yamagata K, Fujiyama S, Ito S, Ueda T, Murata T, Naitou M, Takeyama K, Minami Y, O'Malley BW, Kato S. Maturation of microRNA is hormonally regulated by a nuclear receptor. Molecular cell. 2009; 36:340-347.
42. Guil S, Caceres JF. The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nature structural and molecular biology. 2007; 14:591-596.
43. Michlewski G, Guil S, Semple CA, Caceres JF. Posttranscriptional regulation of miRNAs harboring conserved terminal loops. Molecular cell. 2008; 32:383-393.
44. Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer research. 2009; 69:1221-1229.
45. Lal A, Pan Y, Navarro F, Dykxhoorn DM, Moreau L, Meire E, Bentwich Z, Lieberman J, Chowdhury D. miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nature structural and molecular biology. 2009; 16:492-498.
46. Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, Zhang YK. Evaluation of dynamic change of serum miR-21 and miR-24 in pre-and post-operative lung carcinoma patients. Medical oncology. 2012; 29:3190-3197.
47. Xie L, Wang T, Yu S, Chen X, Wang L, Qian X, Yu L, Ding Y, Zhang C, Liu B. Cell-free miR-24 and miR-30d, potential diagnostic biomarkers in malignant effusions. Clinical biochemistry. 2011; 44:216-220.
48. Brunner S, Herndler-Brandstetter D, Arnold CR, Wiegers GJ, Villunger A, Hackl M, Grillari J, Moreno-Villanueva M, Burkle A, Grubeck-Loebenstein B. Upregulation of miR-24 is associated with a decreased DNA damage response upon etoposide treatment in highly differentiated CD8 (+) T cells sensitizing them to apoptotic cell death. Aging cell. 2012; 11:579-587.
49. Lin SC, Liu CJ, Lin JA, Chiang WF, Hung PS, Chang KW. miR-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis. Oral oncology. 2010; 46:204-208.
50. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M, Iliopoulos D. An HNF4alphamiRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011; 147:1233-1247.
51. Chen L, Zhang A, Li Y, Zhang K, Han L, Du W, Yan W, Li R, Wang Y, Wang K, Pu P, Jiang T, Jiang C, Kang C. MiR-24 regulates the proliferation and invasion of glioma by ST7L via beta-catenin/Tcf-4 signaling. Cancer letters. 2013; 329:174-180.
52. Du WW, Fang L, Li M, Yang X, Liang Y, Peng C, Qian W, O'Malley YQ, Askeland RW, Sugg SL, Qian J, Lin J, Jiang Z, et al. MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. Journal of cell science. 2013; 126:1440-1453.
53. Chhabra R, Dubey R, Saini N. Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Molecular cancer. 2010; 9:232.
54. Caceres JF, Stamm S, Helfman DM, Krainer AR. Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science. 1994; 265:1706-1709.
55. Mayeda A, Krainer AR. Regulation of alternative premRNA splicing by hnRNP A1 and splicing factor SF2. Cell. 1992; 68:365-375.
56. Yang X, Bani MR, Lu SJ, Rowan S, Ben-David Y, Chabot B. The A1 and A1B proteins of heterogeneous nuclear ribonucleoparticles modulate 5' splice site selection in vivo. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91:6924-6928.
57. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic acids research. 2014; 42:D92-97.
58. Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic acids research. 2011; 39:D202-209.
59. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, et al. The genomic and transcriptomic architecture of 2, 000 breast tumors reveals novel subgroups. Nature. 2012; 486:346-352.
60. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumors. Nature. 2012; 490:61-70.
61. Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, Muti P, Strano S, et al. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Annals of oncology. 2013; 24:3082-3088.
62. Gao Y, Liu Y, Du L, Li J, Qu A, Zhang X, Wang L, Wang C. Down-regulation of miR-24-3p in colorectal cancer is associated with malignant behavior. Medical oncology. 2015; 32:362.
63. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, Jessen WJ, Freudenberg J, Chen X, Haigis K, Jegga AG, Kong S, Sakthivel B, Xu H, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome biology. 2007; 8:R131.
64. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast cancer research. 2009; 11:R7.
65. Gaedcke J, Grade M, Jung K, Camps J, Jo P, Emons G, Gehoff A, Sax U, Schirmer M, Becker H, Beissbarth T, Ried T, Ghadimi BM. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes, chromosomes and cancer. 2010; 49:1024-1034.
66. Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A 'metastasis-prone' signature for early-stage mismatchrepair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clinical and experimental metastasis. 2010; 27:83-90.
67. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kwok K, Hanna W, Zubovits J, Armes J, Venter D, Hakimi J, et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:11005-11010.
68. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer cell. 2006; 9:121-132.
69. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J, Ostrowski J. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PloS one. 2010; 5:e13091.
70. Lee SE, Kim SJ, Youn JP, Hwang SY, Park CS, Park YS. MicroRNA and gene expression analysis of melatoninexposed human breast cancer cell lines indicating involvement of the anticancer effect. Journal of pineal research. 2011; 51:345-352.
71. Allemand E, Guil S, Myers M, Moscat J, Caceres JF, Krainer AR. Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:3605-3610.
72. Shimada N, Rios I, Moran H, Sayers B, Hubbard K. p38 MAP kinase-dependent regulation of the expression level and subcellular distribution of heterogeneous nuclear ribonucleoprotein A1 and its involvement in cellular senescence in normal human fibroblasts. RNA biology. 2009; 6:293-304.
73. van der Houven van Oordt W, Diaz-Meco MT, Lozano J, Krainer AR, Moscat J, Caceres JF. The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. The Journal of cell biology. 2000; 149:307-316.
74. Yin JY, Deng ZQ, Liu FQ, Qian J, Lin J, Tang Q, Wen XM, Zhou JD, Zhang YY, Zhu XW. Association between mir-24 and mir-378 in formalin-fixed paraffin-embedded tissues of breast cancer. International journal of clinical and experimental pathology. 2014; 7:4261-4267.
75. Liu R, Fu A, Hoffman AE, Zheng T, Zhu Y. Melatonin enhances DNA repair capacity possibly by affecting genes involved in DNA damage responsive pathways. BMC cell biology. 2013; 14:1.
76. D'Antonio M, D'Onorio De Meo P, Pallocca M, Picardi E, D'Erchia AM, Calogero RA, Castrignano T, Pesole G. RAP: RNA-Seq Analysis Pipeline, a new cloud-based NGS web application. BMC genomics. 2015; 16:S3.
77. Roberts A, Trapnell C, Donaghey J, Rinn JL, Pachter L. Improving RNA-Seq expression estimates by correcting for fragment bias. Genome biology. 2011; 12:R22.
78. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. Journal of biomedical informatics. 2011; 44:839-847.